BN Business News
Add your company to Business Communicator →

Business · 26/05/2022Updated: 10/17/2026 · 1 min read

Gilead Sciences Withdraws FDA Approval for ZYDELIG Indications for Relapsed Lymphoma

Summary

Gilead Sciences, Inc. has voluntarily withdrawn FDA approval for ZYDELIG (idelalisib) Tablets to treat relapsed follicular lymphoma and relapsed small lymphocytic lymphoma, following a request to the FDA.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →